NCT01931098View on ClinicalTrials.gov

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 10, 2015

Primary Completion Date

September 12, 2019

Study Completion Date

September 12, 2019

Conditions

GlioblastomaGlioblastoma MultiformeGliosarcomaBrain NeoplasmsCentral Nervous System Neoplasms

Interventions

DRUG

topotecan

Taken .25 mg orally, daily continuous until progression up to one year.

DRUG

pazopanib

600 mg orally, daily until progression, up to one year.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT01931098 - Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab | Biotech Hunter | Biotech Hunter